The highest-risk AEDs were zonisamide, rufinamide, clorazepate, lamotrigine, carbamazepine, and phenytoin.
News from the FDA/CDC
The central nervous system depressant was approved for the treatment of cataplexy and excessive daytime sleepiness.
MS relapse can have a significant impact on patients’ short- and long-term function, quality of life, and finances. Here’s what to look for—and...
A pivotal phase 2/3 trial of bertilimumab will begin next year, according to the company.